- Home
- CLPT vs RLMD Comparison
CLPT vs RLMD Comparison
Compare CLPT & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPT | RLMD |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.9M | 461.9M |
| IPO Year | 2009 | 2012 |
Fundamental Metrics
Financial Performance| Metric | CLPT | RLMD |
|---|---|---|
| Price | $9.15 | $3.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $23.50 | $10.75 |
| AVG Volume (30 Days) | 649.3K | ★ 1.4M |
| Earning Date | 10-28-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,971,000.00 | $13,070.00 |
| Revenue This Year | $32.54 | N/A |
| Revenue Next Year | $15.41 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 17.78 | ★ 154.83 |
| 52 Week Low | $8.27 | $2.15 |
| 52 Week High | $27.27 | $8.00 |
Technical Indicators
Market Signals| Indicator | CLPT | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 31.63 | 39.10 |
| Support Level | $8.61 | $3.13 |
| Resistance Level | $15.30 | $3.55 |
| Average True Range (ATR) | 0.48 | 0.21 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 5.20 | 39.57 |
Price Performance
Historical ComparisonAbout CLPT ClearPoint Neuro Inc.
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.